By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are a first-time founder who has heard the phrase “This isn’t a good time to be raising for X,” where X The post Best Practices for Pitching, Geared Towards First-Time Founders appeared first on LifeSciVC.| LifeSciVC
Over 200 GLP1 obesity programs are in development today. More than 300 PD1/PDL1 cancer programs exist. Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While The post Biotech Wisdom Of The Crowds: Competition And Capitalism appeared first on LifeSciVC.| LifeSciVC
The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why? Because there are so few being created The post Biotech Venture Creation: The Benefits Of Scarcity appeared first on LifeSciVC.| LifeSciVC